$Moderna, Inc.(MRNA)$
Stéphane Bancel, CEO of Moderna, said the following in the earnings report.
“Today’s earnings represent a strong second quarter performance, with $10.8 billion in revenue for the first half of the year. We continue to have advance purchase agreements for expected delivery in 2022 of around $21 billion of sales.”
MRNA Stock: More Vaccines Are on the Way
Moderna also notes that its development pipeline is strong with four vaccines for infectious diseases in Phase 3 clinical trials. It also expects “important data from proof-of-concept studies in rare diseases and immuno-oncology,” later this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments